An interventional study of Mechanical Thrombectomy (Penumbra System with Thunderbolt) in Acute Ischemic Stroke and Large Vessel Occlusion, sponsored by Penumbra Inc.. Completed at 32 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Penumbra Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Ischemic Stroke by Penumbra Inc. — 2 open to participants now, 2 under way, none of them phase 3. Ischemic Stroke · Penumbra Inc..
Among the 14 studies in Ischemic Stroke by Penumbra Inc., this one is the only one that started in 2022, is one of 3 with no phase, and was the 12th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →2 of the 14 studies in Ischemic Stroke by Penumbra Inc. are open now, in 6 countries. Recruiting first, the newest first:
Penumbra Inc. · Sites in United States
Ages 18+
Penumbra Inc. · Sites in Australia, Canada, France and 2 more countries
Ages 18–80
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2022.
This study's enrollment of 216 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 146 across the 5 interventional studies, 204 across the 9 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Penumbra Inc. is the lead sponsor of 33 studies on the registry; 4 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Ischemic Stroke by Penumbra Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to demonstrate the safety and efficacy of the Penumbra System including Thunderbolt Aspiration Tubing (Thunderbolt) in a population presenting with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion (LVO) who are eligible for mechanical thrombectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Use of Penumbra System including Thunderbolt in patients with acute ischemic stroke secondary to intracranial large vessel occlusion who are eligible for mechanical thrombectomy
Device: Mechanical Thrombectomy (Penumbra System with Thunderbolt)
Subject will receive Penumbra System with Thunderbolt
Efficacy Endpoint: Angiographic Revascularization
Angiographic revascularization of the occluded target vessel Post-Penumbra as defined by mTICI 2b or higher. \*mTICI ranges from 0-3, with higher grading representing better outcome
Time frame: Up to Procedure Completion
Efficacy Endpoint: Angiographic Revascularization After First Pass
Angiographic revascularization of the occluded target vessel after first pass as defined by mTICI 2b or higher \*mTICI ranges from 0-3, with higher grading representing better outcome
Time frame: During Index Procedure
Efficacy Endpoint: Angiographic Revascularization
Angiographic revascularization of the occluded target vessel Post-Penumbra as defined by mTICI 2c or higher \*mTICI ranges from 0-3, with higher grading representing better outcome
Time frame: Up to Procedure Completion
Efficacy Endpoint: Time to Revascularization
Time from arterial puncture to successful revascularization of the target vessel (mTICI 2b-3), or to the final angiogram if successful revascularization is not achieved
Time frame: During Index Procedure
Efficacy Endpoint: Modified Rankin Scale (mRS)
Functional outcomes measured by mRS 0-2 at 90 days (0 no symptoms - 5 severe disability)
Time frame: 90 Days Post-Procedure
Safety Endpoint: Rate of Symptomatic Intracranial Hemorrhage (sICH)
Occurrence of symptomatic intracranial hemorrhages (sICH) at 24 hours
Time frame: 24 hours Post-Procedure
Safety Endpoint: All-cause Mortality
All-cause mortality at 90 days post-procedure
Time frame: 90 Days Post-Procedure
Safety Endpoint: Serious Adverse Events (SAEs)
Incidence of device related, and/or procedure related Serious Adverse Events (SAEs) within 24 hours post-procedure
Time frame: Up to 24 hours Post-Procedure
| Milestone | Single Arm |
|---|---|
| Started | 216 |
| Completed | 182 |
| Not completed | 34 |
Angiographic revascularization of the occluded target vessel Post-Penumbra as defined by mTICI 2b or higher. \*mTICI ranges from 0-3, with higher grading representing better outcome
| Participants | Single Arm |
|---|---|
| Efficacy Endpoint: Angiographic Revascularization | 189 |
Angiographic revascularization of the occluded target vessel after first pass as defined by mTICI 2b or higher \*mTICI ranges from 0-3, with higher grading representing better outcome
| Participants | Single Arm |
|---|---|
| Efficacy Endpoint: Angiographic Revascularization After First Pass | 140 |
Angiographic revascularization of the occluded target vessel Post-Penumbra as defined by mTICI 2c or higher \*mTICI ranges from 0-3, with higher grading representing better outcome
| Participants | Single Arm |
|---|---|
| Efficacy Endpoint: Angiographic Revascularization | 152 |
Time from arterial puncture to successful revascularization of the target vessel (mTICI 2b-3), or to the final angiogram if successful revascularization is not achieved
| minutes | Single Arm |
|---|---|
| Efficacy Endpoint: Time to Revascularization | 27 ± 26 |
Functional outcomes measured by mRS 0-2 at 90 days (0 no symptoms - 5 severe disability)
| Participants | Single Arm |
|---|---|
| Efficacy Endpoint: Modified Rankin Scale (mRS) | 112 |
Occurrence of symptomatic intracranial hemorrhages (sICH) at 24 hours
| Participants | Single Arm |
|---|---|
| Safety Endpoint: Rate of Symptomatic Intracranial Hemorrhage (sICH) | 2 |
All-cause mortality at 90 days post-procedure
| Participants | Single Arm |
|---|---|
| Safety Endpoint: All-cause Mortality | 24 |
Incidence of device related, and/or procedure related Serious Adverse Events (SAEs) within 24 hours post-procedure
| Participants | Single Arm |
|---|---|
| Safety Endpoint: Serious Adverse Events (SAEs) | 6 |
Collected over Procedure, 24-Hour Follow-Up (+/- 12 hours), 7-10 Day and/or Discharge, 30 Day Follow-Up (+/- 7 Days), 90 Day Follow-Up (+/- 14 Days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single Arm | 24/205 (11.7%) | 89/216 (41.2%) | 126/216 (58.3%) |
| Event | Single Arm |
|---|---|
| Stroke in evolutionNervous system disorders | 9/216 |
| Atrial fibrillationCardiac disorders | 8/216 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 8/216 |
| Acute kidney injuryRenal and urinary disorders | 5/216 |
| Pneumonia aspirationInfections and infestations | 4/216 |
| Brain oedemaNervous system disorders | 4/216 |
| Cerebral artery occlusionNervous system disorders | 4/216 |
| AnaemiaBlood and lymphatic system disorders | 3/216 |
| Acute myocardial infarctionCardiac disorders | 3/216 |
| DysphagiaGastrointestinal disorders | 3/216 |
| Event | Single Arm |
|---|---|
| HeadacheNervous system disorders | 14/216 |
| Cerebral haemorrhageNervous system disorders | 13/216 |
| Deep vein thrombosisVascular disorders | 12/216 |
| Atrial fibrillationCardiac disorders | 11/216 |
| Haemorrhagic transformation strokeNervous system disorders | 10/216 |
| Urinary tract infectionInfections and infestations | 9/216 |
| Acute kidney injuryRenal and urinary disorders | 9/216 |
| Urinary retentionRenal and urinary disorders | 9/216 |
| ConstipationGastrointestinal disorders | 8/216 |
| HypotensionVascular disorders | 8/216 |
| Age, Continuous(years) | Single Arm |
|---|---|
| Mean | 64.8 ± 11.55 |
| Sex: Female, Male(Participants) | Single Arm |
|---|---|
| Female | 98 |
| Male | 118 |
| Race (NIH/OMB)(Participants) | Single Arm |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 40 |
| White | 160 |
| More than one race | 5 |
| Unknown or Not Reported | 6 |
| Ethnicity (NIH/OMB)(Participants) | Single Arm |
|---|---|
| Hispanic or Latino | 23 |
| Not Hispanic or Latino | 169 |
| Unknown or Not Reported | 24 |
| Body Mass Index(kg/m2) | Single Arm |
|---|---|
| Mean | 29.8 ± 6.96 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Sep 2024, 25 months.
Results were first posted in Nov 2026, 2 years 1 month after primary completion.
Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 25 months is close to that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.